1:30 PM SIGN-IN • 2:00 PM - 3:30 PM
BANDOL 1 (NEW WYNN SPACE)
CE: Hemophilia A: Navigating the Therapeutic Landscape
In the management of hemophilia A, prophylactic therapy is considered the standard of care; without prophylactic therapy, patients may experience up to 30 bleeding episodes per year. However, patients can develop inhibitors to treatment, increasing the risk of bleeding. Earlier treatments for hemophilia A presented challenges, such as tolerability issues due to the use of albumin or animal products or required frequent infusions due to a short half-life. In the past decade, the hemophilia A landscape has expanded and improved quality of life for patients with hemophilia. This symposium features a hemophilia expert and specialty infusion pharmacist, and will characterize the burden of hemophilia A, investigate clinical data for current and emerging therapies, and discuss management strategies.